Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial

Autor: Madhi, SA, Kwatra, G, Richardson, SI, Koen, AL, Baillie, V, Cutland, CL, Fairlie, L, Padayachee, SD, Dheda, K, Barnabas, SL, Bhorat, QE, Briner, C, Ahmed, K, Aley, PK, Bhikha, S, Bhorat, AE, Esmail, A, Horne, E, Kaldine, H, Mukendi, CK, Madzorera, VS, Manamela, NP, Masilela, M, Hermanus, ST, Motlou, T, Mzindle, N, Oelofse, S, Patel, F, Rhead, S, Rossouw, L, Taoushanis, C, van Eck, S, Lambe, T, Gilbert, SC, Pollard, AJ, Moore, PL, Izu, A

Publikováno v: The Lancet Infectious Diseases. 23:295-306

Background COVID-19 vaccine rollout is lagging in Africa, where there has been a high rate of SARS-CoV-2 infection. We aimed to evaluate the effect of SARS-CoV-2 infection before vaccination with the ChAdOx-nCoV19 (AZD1222) vaccine on antibody respon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e491413796b8d66b44a6cebc3f4e218
https://doi.org/10.1016/s1473-3099(22)00596-5

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

Autor: Stuart, ASV, Shaw, RH, Liu, X, Greenland, M, Aley, PK, Andrews, NJ, Cameron, JC, Charlton, S, Clutterbuck, EA, Collins, AM, Darton, T, Dinesh, T, Duncan, CJA, England, A, Faust, SN, Ferreira, DM, Finn, A, Goodman, AL, Green, CA, Hallis, B, Heath, PT, Hill, H, Horsington, BM, Lambe, T, Lazarus, R, Libri, V, Lillie, PJ, Mujadidi, YF, Payne, R, Plested, EL, Provstgaard-Morys, S, Ramasamy, MN, Ramsay, M, Read, RC, Robinson, H, Screaton, GR, Singh, N, Turner, DPJ, Turner, PJ, Vichos, I, White, R, Nguyen-Van-Tam, JS, Snape, MD, Com-COV2 Study Group

Publikováno v: Lancet (London, England)
Snape, M D 2022, ' Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2) : a single-blind, randomised, phase 2, non-inferiority trial ', Lancet, vol. 399, no. 10319, pp. 36-49 . https://doi.org/10.1016/S0140-6736(21)02718-5

Background Given the importance of flexible use of different COVID-19 vaccines within the same schedule to facilitate rapid deployment, we studied mixed priming schedules incorporating an adenoviral-vectored vaccine (ChAdOx1 nCoV-19 [ChAd], AstraZene

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e72507942631237263460b52b50669b5
https://doi.org/10.1016/s0140-6736(21)02718-5

T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa

Autor: McMahon, WC, Kwatra, G, Izu, A, Koen, AL, Greffrath, J, Fairlie, L, Patel, F, Mukendi, CK, Mbele, NJ, Lala, R, Burgers, WA, Nunes, MC, Cutland, CL, Gilbert, SC, Lambe, T, Pollard, AJ, Madhi, SA

Publikováno v: AIDS (London, England). 37(1)

Objective(s):This study aimed to investigatesevere acute respiratory syndrome coronavirus 2(SARS-CoV-2)-specificT-cell responses14 days after single-doseChAdOx1 nCoV-19(AZD1222) vaccination in black Africans with and without HIV in South Africa, as w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e25ac6564518edd42c4373c2bf6da60
https://pubmed.ncbi.nlm.nih.gov/36476455

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Viral vector vaccines

Autor: McCann, N, O'Connor, D, Lambe, T, Pollard, AJ

Over the past two years, the SARS-CoV-2 pandemic has highlighted the impact that emerging pathogens can have on global health. The development of new and effective vaccine technologies is vital in the fight against such threats. Viral vectors are a r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de76965f660561122b543c7dbd07f882
https://ora.ox.ac.uk/objects/uuid:89ba72ca-e810-4a4f-ac3c-2a5f64d76a3a